SDC2 and colorectal carcinoma: A meta-analysis by Wang et al., which used data from 12 studies with a total of 1574 patients and 1945 healthy individuals, concluded that SDC2 methylation analysis could be considered a potential new biomarker for CRC screening (pooled sensitivity of 0.81 and specificity of 0.95) [35].